115 related articles for article (PubMed ID: 1554942)
1. Pharmacogenetics: Part II.
Gibaldi M
Ann Pharmacother; 1992 Feb; 26(2):255-61. PubMed ID: 1554942
[No Abstract] [Full Text] [Related]
2. Debrisoquine 4-hydroxylation (CYP2D6) polymorphism in Jordanians.
Hadidi HF; Cholerton S; Monkman SC; Armstrong M; Irshaid YM; Rawashdeh NM; Daly AK; Idle JR
Pharmacogenetics; 1994 Jun; 4(3):159-61. PubMed ID: 7920696
[No Abstract] [Full Text] [Related]
3. [Role of pharmacogenetics in psychopharmacotherapy].
Gram LF
Encephale; 1991; 17 Spec No 1():123-5. PubMed ID: 1864259
[TBL] [Abstract][Full Text] [Related]
4. Interpretation of a simple PCR analysis of the CYP2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/sparteine genetic polymorphism.
Douglas AM; Atchison BA; Somogyi AA; Drummer OH
Pharmacogenetics; 1994 Jun; 4(3):154-8. PubMed ID: 7920695
[No Abstract] [Full Text] [Related]
5. Gene-environment interaction in parkinson's disease. The case of CYP2D6 gene polymorphism.
Landi MT; Ceroni M; Martignoni E; Bertazzi PA; Caporaso NE; Nappi G
Adv Neurol; 1996; 69():61-72. PubMed ID: 8615186
[No Abstract] [Full Text] [Related]
6. Debrisoquine hydroxylation genotype in familial forms of idiopathic Parkinson's disease.
Bordet R; Broly F; Destée A; Libersa C
Adv Neurol; 1996; 69():97-100. PubMed ID: 8615190
[No Abstract] [Full Text] [Related]
7. Variants of human microsomal enzymes.
Davies DS; Boobis AR
Biochem Soc Trans; 1983 Aug; 11(4):459-60. PubMed ID: 6617977
[No Abstract] [Full Text] [Related]
8. Genetic basis for differences in debrisoquin polymorphism between a Spanish and other white populations.
Agúndez JA; Martínez C; Ledesma MC; Ladona MG; Ladero JM; Benítez J
Clin Pharmacol Ther; 1994 Apr; 55(4):412-7. PubMed ID: 7909282
[TBL] [Abstract][Full Text] [Related]
9. The pharmacogenetics of codeine hypoalgesia.
Sindrup SH; Brøsen K
Pharmacogenetics; 1995 Dec; 5(6):335-46. PubMed ID: 8845855
[TBL] [Abstract][Full Text] [Related]
10. Debrisoquine hydroxylation in a Polish population.
Kunicki PK; Sitkiewicz D; Pawlik A; Bielicka-Sulzyc V; Borowiecka E; Gawrońska-Szklarz B; Sterna R; Matsumoto H; Radziwoń-Zaleska M
Eur J Clin Pharmacol; 1995; 47(6):503-5. PubMed ID: 7768252
[TBL] [Abstract][Full Text] [Related]
11. Stereoselective disposition of carvedilol is determined by CYP2D6.
Zhou HH; Wood AJ
Clin Pharmacol Ther; 1995 May; 57(5):518-24. PubMed ID: 7768074
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics. Enigmatic variations.
Idle J
Nature; 1988 Feb; 331(6155):391-2. PubMed ID: 3340186
[No Abstract] [Full Text] [Related]
13. [Human biodiversity and its effects on the pharmacological variability: CYP2D6 and NAT2 enzymes in Amerind populations of Panama, Colombia and Costa Rica].
Jorge LF; Arias TD
Rev Med Panama; 1995 Sep; 20(3):98-107. PubMed ID: 8668827
[TBL] [Abstract][Full Text] [Related]
14. Prediction of debrisoquine phenotype.
Wolf CR; Moss JE; Miles JS; Gough AC; Spurr NK
Lancet; 1991 Mar; 337(8741):623. PubMed ID: 1671985
[No Abstract] [Full Text] [Related]
15. Pharmacogenetics: Part I.
Gibaldi M
Ann Pharmacother; 1992 Jan; 26(1):121-6. PubMed ID: 1606333
[No Abstract] [Full Text] [Related]
16. Lack of congruence of S-carboxymethyl-L-cysteine sulphoxidation and debrisoquine 4-hydroxylation in a Caucasian population.
Haley CS; Waring RH; Mitchell SC; Shah RR; Idle JR; Smith RL
Xenobiotica; 1985 May; 15(5):445-50. PubMed ID: 4036168
[TBL] [Abstract][Full Text] [Related]
17. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.
Dahl ML; Johansson I; Bertilsson L; Ingelman-Sundberg M; Sjöqvist F
J Pharmacol Exp Ther; 1995 Jul; 274(1):516-20. PubMed ID: 7616439
[TBL] [Abstract][Full Text] [Related]
18. Debrisoquine hydroxylase gene polymorphism in Parkinson's disease and amyotrophic lateral sclerosis.
Ray-Chaudhuri K; Smith C; Gough AC; Novak N; Chamoun V; Wolf CR; Leigh PN
J Neurol Neurosurg Psychiatry; 1995 Jan; 58(1):109. PubMed ID: 7823053
[No Abstract] [Full Text] [Related]
19. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
Broly F; Meyer UA
Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
[TBL] [Abstract][Full Text] [Related]
20. Molecular genetics of the debrisoquin-sparteine polymorphism.
Gonzalez FJ; Meyer UA
Clin Pharmacol Ther; 1991 Sep; 50(3):233-8. PubMed ID: 1680592
[No Abstract] [Full Text] [Related]
[Next] [New Search]
